AP
VIRX

Alydar Partners’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Alydar Partners’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-2,169
Closed -$2.97M – 138
2014
Q2 		$2.97M Sell
2,169
-453
-17% -$526K 0.25% 72
2014
Q1 		$3.64M Buy
2,622
+48
+2% +$55.8K 0.36% 61
2013
Q4 		$2.56M Buy
2,574
+2,098
+441% +$2.17M 0.26% 73
2013
Q3 		$496K Buy
+476
New +$509K 0.04% 105

Other funds holding VIRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCP
Lamond Capital Partners San Francisco, California $14.3M AUM 30.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Alydar Partners's VIRX Position: Q3 2014 in Review

Alydar Partners sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2014, closing a stake of 2,169 shares — an estimated $2.97M sold.

Alydar Partners first reported a position in VIRX in Q3 2013 and held it in 4 quarters. The position peaked at $3.64M in Q1 2014. 104 funds tracked by Wall St. Rank hold VIRX as of Q3 2014.

  • Alydar Partners reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2014 after selling out during the quarter.
  • Alydar Partners sold 2,169 Viracta Therapeutics, Inc. Common Stock shares in Q3 2014, an estimated $2.97M.
  • Alydar Partners first reported a position in Viracta Therapeutics, Inc. Common Stock in Q3 2013 and held it in 4 quarters.
  • Alydar Partners's Viracta Therapeutics, Inc. Common Stock position peaked at $3.64M in Q1 2014.
  • 104 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2014.

Based on Alydar Partners's 13F filing for Q3 2014, filed 14 Nov 2014.